GlassScriptPhysician profile
Robert R Tirado
NPI 1558514836
$2,710.40
in general payments reported to CMS, 2019-2025
31 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.93 · 2022: $531 · 2023: $1,080 · 2024: $885 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.84 | 2021-2025 | |
| Medtronic, INC. | $548.93 | 2023-2025 | Minimed 780g, Minimed 770g |
| Otsuka America Pharmaceutical, INC. | $233.47 | 2022-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $143.16 | 2022-2023 | Aristada, Lybalvi |
| Corium, LLC | $97.58 | 2024 | Azstarys, Azstarys |
| Lundbeck LLC | $76.17 | 2023-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $61.37 | 2022 | |
| Idorsia Pharmaceuticals US INC | $59.71 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $52.74 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $47.73 | 2022-2024 | Uzedy |
| Axsome Therapeutics, INC. | $46.83 | 2023-2024 | Auvelity |
| Depuy Synthes Sales INC. | $45.81 | 2021-2023 | Orthovisc |
| Takeda Pharmaceuticals U.S.A., INC. | $30.50 | 2022-2024 | Trintellix |
| Almatica Pharma LLC | $27.22 | 2023 | Loreev Xr, Sertraline Hcl, Gralise |
| Glaxosmithkline, LLC. | $25.60 | 2022-2023 | Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.18 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.95 | 2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $17.60 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.63 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $15.31 | 2023 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $14.87 | 2023 | Linzess |
| Neos Therapeutics, LP | $14.79 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.68 | 2024 | Qelbree |
| Bausch Health US, LLC | $14.68 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.34 | 2024 | Voquezna |
| Tolmar, INC. | $14.12 | 2024 | |
| Tris Pharma INC | $14.08 | 2023 | Dyanavel Xr |
| Lilly USA, LLC | $14.01 | 2024 | Zepbound |
| Noven Therapeutics, LLC | $13.90 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.42 | 2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tirado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.